MetLife Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

MetLife Investment Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$709K	Buy	+2,660	New	+$621K	﹤0.01%	1719

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

MetLife Investment Management's ASND Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 2,660 shares worth $709K. The stake represents ﹤0.01% of the portfolio and ranks #1719 among its holdings.

311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

MetLife Investment Management held 2,660 shares of Ascendis Pharma A/S worth $709K as of Q2 2026.
Ascendis Pharma A/S was a new MetLife Investment Management position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1719 holding.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.